Buenavista, Maura E.
HRN: 20-72-50 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
04/09/2024
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
04/09/2024
04/09/2024
IVT
500mg
Q8
T/c Lung Abscess
Waiting Final Action
Indication: Empiric Type of Infection: Pneumonia Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes